Logistic regression model of fotemustine toxicity combining independent Phase II studies

Cancer

Volumn 78, Issue 9, 1996, Pages 1980-1987

  Raymond, Eric ^a,d   Haon, Corinne ^b   Boaziz, Catherine ^c   Coste, Maylis ^c  

^a HÔPITAL SAINT ANTOINE   (France)

^b Processus Statistique   (France)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^d CTRC Institute for Drug Development   (United States)

Author keywords

chemotherapy; fotemustine; logistic regression method; multifactorial analysis; nitrosourea; quality of life; toxicity

Indexed keywords

FOTEMUSTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD TOXICITY; BRAIN TUMOR; CANCER CLASSIFICATION; CANCER STAGING; CLINICAL TRIAL; EARLY DIAGNOSIS; FEMALE; HEAD AND NECK CANCER; HUMAN; LIVER TOXICITY; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; NAUSEA; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANEMIA; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II; FEMALE; HUMANS; LEUKOPENIA; LOGISTIC MODELS; MALE; MIDDLE AGED; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; THROMBOCYTOPENIA;

EID: 0029842433     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19961101)78:9<1980::AID-CNCR20>3.0.CO;2-T     Document Type: Article

References (34)

1. Chalmers TC, Levin H, Sacks HS, Reitman D, Barrier J, Nagalingam R. Meta-analysis of clinical trials as a scientific discipline: control of bias and comparison with large cooperative trials. Stat Med 1987;6:315-25.
2. Berlin JA, Laird NM, Sacks HS, Chalmers TC. A comparison of statistical methods for combining event rates from clinical trials, Stat Med 1989;8:141-51.
3. Colvin M, Chabner BA. Alkylating agents. In: Chabner BA, Collins JM, editors. Cancer chemotherapy principles and practice. 2nd edition. Philadelphia: J.B. Lippincott, 1990: 276-313.
4. Khayat D, Lokiec F, Bizzari JP, Weil M, Meeus L, Jacquillat C. Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule. Cancer Res 1987;47:6782-5.
5. Aapro MS. Advances in systemic treatment of malignant melanoma. Eur J Cancer 1993;29:613-7.
6. Retsas S, Bayliss M, Sheikh N, Chong SL, Bafaloukos D. Chemotherapy of malignant melanoma: the European experience. Rev Med Interne 1990;11:51-8.
7. Jacquillat C, Khayat D, Banzet P, Weil M, Fumoleau P, Bizzari JP. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 patients with disseminated malignant melanoma including patients with cerebral metastasis. Cancer 1990;66:1873-8.
8. Khayat D, Cour V, Bizzari JP, Aigner K, Borel C, Jacquillat C. Fotemustine (S 10036) in the intra-arterial treatment of liver metastasis from malignant melanoma. A phase II study. Am J Clin Oncol 1991;14:400-4.
9. Khayat D, Avril MF, Gerard B, Bertrand P, Bizzari JP, Cour V. Fotemustine: an overview of its clinical activity in disseminated malignant melanoma. Melanoma Res 1992;2:147-51.
10. Khayat D, Bizzari JP, Frenay M, Naman H, Weil M, Jacquillat C. Interim report of phase II study of new nitrosourea S 10036 in disseminated malignant melanoma. J Natl Cancer Inst 1988;17:1407-8.
11. Aapro M, Becquart D, Kleeberg U, Wils J, Michel J, Gerard B. International phase II trial of fotemustine in advanced malignant melanoma. Invest New Drugs 1989;9:436.
12. Jacquillat C, Khayat D, Banzet P, Weil M, Fumoleau P, Bizzari JP. Multicentric study of the nitrosourea fotemustine (S 10036) in advanced malignant melanoma (AMM) including patients with cerebral metastases. In: Jacquillat C, Weil M, Khayat D, editors. Neo-adjuvant chemotherapy. Paris: John Libbey Eurotext Ltd, 1988:787-90.
13. Jacquillat C, Khayat D, Banzet P, Weil M, Avril MF, Bizzari LP. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma. Cancer Chemother Pharmacol 1990;25:263-6.
14. Grisoli F, Namer M, Bourdin S, Poisson M, Derlon JM, Giroux B. Fotemustine (S 10036) in the treatment of malignant gliomas in adults. Invest New Drugs 1989;9:431.
15. Khayat D, Giroux B, Berille J, Cour V, Gerard B, Bizzari JP. Fotemustine in the treatment of brain primary tumors and metastases. Cancer Invest 1994;12:414-20.
16. Frenay M, Giroux B, Khoury S, Derlon JM, Namer M. Phase II study of fotemustine in recurrent supratentorial malignant gliomas. Eur J Cancer 1991;27:852-6.
17. Le Chevalier T, Monnier A, Douillard JY, Pujol JL, Riviere A, Bizzari JP. Phase II study of fotemustine in the treatment of inoperable non small cell lung carcinoma (NSCLC): final report. Eur J Cancer 1993;1:5161.
18. Frenay M, Biron P, Poisson M, Giroux B. Tumor exposure to fotemustine in malignant glioma. The higher the better? Eur J Cancer 1993;1:5189.
19. Efron B. The efficiency of logistic regression compared to normal discriminant analysis. J Am Stat Assoc 1975;70:892-8.
20. Moriguchi S, Hayashi Y, Nose Y, Maehara Y, Korenaga D, Sugimachi K. A comparison of the logistic regression and the Cox proportional hazard models in retrospective studies on the prognosis of patients with gastric cancer. J Surg Oncol 1993;52:9-13.
21. Drescher K, Schill W. Attributable risk estimation from case-control data via logistic regression. Biometrics 1991;47:1247-56.
22. Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 1993;12:1293-316.
23. Rao VR, Levy K, Lustik M. Logistic regression of inhalation toxicities of perchlorethylene: application in noncancer risk assessment. Regul Toxicol Pharmacol 1993;18:233-47.
24. Preston Martin S, Yu MC, Benton B, Henderson BE. N-Nitroso compounds and childhood brain tumors: a case control study. Cancer Res 1982;42:5240-5.
25. Coughlin SS, Nass CC, Pickle LW, Trock B, Bunin G. Regression methods for estimating attributable risk in population-based case-control studies: a comparison of additive and multiplicative models. Am J Epidemiol 1991;133:305-13.
26. Brazer SR, Pancotto FS, Long TT, Harrell FE, Lee KL, Pryor DB. Using ordinal logistic regression to estimate the likelihood of colorectal neoplasia. J Clin Epidemiol 1991;44:1263-70.
27. Hosmer DW, Lemeshow S. Applied logistic regression. 1st edition. New York: John Wiley & Sons, 1994:1-80.
28. Mc Cullagh P. Regression models for ordinal data. J R Stat Soc 1980;42:109-42.
29. Gordon NH, Willson JK. Using toxicity grades in the design and analysis of cancer phase I clinical trials. Stat Med 1992;11:2063-75.
30. Chevret S. The continual reassessment method in cancer phase I clinical trial: a simulation study. Stat Med 1993;12:1093-108.
31. Hosmer DW, Lemeshow S. Goodness-of-fit tests for the multiple logistic regression model. Commun Statist Part A Theor Meth 1980;10:1043-69.
32. Baldwin JG. Hematopoietic function in the elderly. Arch Intern Med 1988;148:2544-6.
33. Newell DR, Gore ME. Toxicity of alkylating agents: clinical characteristics and pharmacokinetic determinants. In: Powis G, Hacker MP, editors, The toxicity of anticancer drugs. New York: Pergamon Press, 1991:44-62.
34. Calabresi F, Aapro M, Becquart D, Dirix L, Wils J, Gerard B. Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanoma. Ann Oncol 1991;2:377-8.